Biologic and Immunologic Therapies for Ovarian Cancer Export

@article{citeulike:6083397, abstract = {Biologic therapy of ovarian cancer has been conducted using nonspecific biologic response modifiers, cytokines, monoclonal antibodies (MAbs), vaccines, and gene therapy. Antibodies directed toward her2/neu have also been studied. Phase I and II gene therapy trials using adenoviral vectors containing a wild-type or modified p53 have shown that the treatment is well tolerated. Phase II and III trials are ongoing with MAbs directed against CA-125 (MAb B43.13) and an antibody directed against HMFG1 (anti-HMFG1-yttrium-90-labeled antibody). The trials have shown that these agents are well tolerated and that immunologic responses occur, although the ultimate clinical value of these agents remains to be determined. Prolonged survival after MAb B43.13 treatment has been correlated with changes in several immune parameters, including human antimurine antibody, Ab2, anti-CA-125 antibody development, and induced T-cell immunity. Clinical trials using a MAb directed toward the encoded products of her2/neu have shown minimal activity against ovarian cancer in a phase I and II trial conducted by the Gynecologic Oncology Group. Cytokine therapies have been administered systemically and intraperitoneally. Intracavitary interferon alfa, interferon gamma, and interleukin-2 alone or in combination with cytotoxic therapy in phase I and II trials demonstrated intraperitoneal lymphoid cell stimulation and produced antitumor responses. A randomized trial of chemotherapy with or without interferon gamma in primary treatment produced a response and a progression-free survival advantage in the arm that incorporated the interferon gamma, without a statistically significant benefit in overall survival. A phase III study of interferon gamma in combination with first-line chemotherapy is currently ongoing. 10.1200/JCO.2003.01.517}, author = {Berek, Jonathan S. and Schultes, Birgit C. and Nicodemus, Christopher F.}, citeulike-article-id = {6083397}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2003.01.517}, citeulike-linkout-1 = {http://jco.ascopubs.org/content/21/10_suppl/168s.abstract}, citeulike-linkout-2 = {http://jco.ascopubs.org/content/21/10_suppl/168s.full.pdf}, citeulike-linkout-3 = {http://view.ncbi.nlm.nih.gov/pubmed/12743131}, citeulike-linkout-4 = {http://www.hubmed.org/display.cgi?uids=12743131}, day = {15}, doi = {10.1200/JCO.2003.01.517}, journal = {J Clin Oncol}, keywords = {cancer, ovarian}, month = {May}, number = {10S}, pages = {168s--174}, posted-at = {2009-11-07 22:31:57}, priority = {2}, title = {Biologic and Immunologic Therapies for Ovarian Cancer}, url = {http://dx.doi.org/10.1200/JCO.2003.01.517}, volume = {21}, year = {2003} }

TY - JOUR ID - citeulike:6083397 L3 - citeulike-article-id:6083397 N2 - Biologic therapy of ovarian cancer has been conducted using nonspecific biologic response modifiers, cytokines, monoclonal antibodies (MAbs), vaccines, and gene therapy. Antibodies directed toward her2/neu have also been studied. Phase I and II gene therapy trials using adenoviral vectors containing a wild-type or modified p53 have shown that the treatment is well tolerated. Phase II and III trials are ongoing with MAbs directed against CA-125 (MAb B43.13) and an antibody directed against HMFG1 (anti-HMFG1-yttrium-90-labeled antibody). The trials have shown that these agents are well tolerated and that immunologic responses occur, although the ultimate clinical value of these agents remains to be determined. Prolonged survival after MAb B43.13 treatment has been correlated with changes in several immune parameters, including human antimurine antibody, Ab2, anti-CA-125 antibody development, and induced T-cell immunity. Clinical trials using a MAb directed toward the encoded products of her2/neu have shown minimal activity against ovarian cancer in a phase I and II trial conducted by the Gynecologic Oncology Group. Cytokine therapies have been administered systemically and intraperitoneally. Intracavitary interferon alfa, interferon gamma, and interleukin-2 alone or in combination with cytotoxic therapy in phase I and II trials demonstrated intraperitoneal lymphoid cell stimulation and produced antitumor responses. A randomized trial of chemotherapy with or without interferon gamma in primary treatment produced a response and a progression-free survival advantage in the arm that incorporated the interferon gamma, without a statistically significant benefit in overall survival. A phase III study of interferon gamma in combination with first-line chemotherapy is currently ongoing. 10.1200/JCO.2003.01.517 IS - 10S JF - J Clin Oncol EP - 174 TI - Biologic and Immunologic Therapies for Ovarian Cancer VL - 21 SP - 168s KW - cancer KW - ovarian AU - Berek, Jonathan AU - Schultes, Birgit AU - Nicodemus, Christopher PY - 2003/05/15/ UR - http://dx.doi.org/10.1200/JCO.2003.01.517 ER -